Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Advanced Chart

Key Stats

Today's Range
$3.59
$3.69
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
635,008 shs
Average Volume
648,892 shs
Market Capitalization
$40.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Cardiff Oncology announces second patent for onvansertib combination
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) issued its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

Cardiff Oncology shares reverse split on the morning of Wednesday, February 20th 2019.The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA Royalty (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.41 million
Net Margins
-3,688.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250 thousand
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
3.89

Miscellaneous

Free Float
N/A
Market Cap
$40.30 million
Optionable
Not Optionable
Beta
1.04
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:TROV) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners